Indian Pharma Regaining Form, Helped By Easing US Price Pressures
Indian drug makers are looking in much better shape as US pricing pressures ease and the domestic market regains its double-digit growth, analysts say.
You may also be interested in...
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
The active pharmaceuticals ingredients segment in India appears to be coming into its own, alongside signs of a revival in the overall sales growth of Indian generic firms in FY2019, a study by an Indian investment banking and consulting services firm has indicated.
Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.